期刊文献+

镁极化液与1,6-二磷酸果糖治疗射血分数正常心力衰竭的临床效果 被引量:2

Clinical effect of Mg-GIK combined with FDP treating heart failure with normal ejection fraction
下载PDF
导出
摘要 目的探讨镁极化液(Mg-GIK)与1,6-二磷酸果糖(FDP)治疗射血分数正常心力衰竭(HFNEF)的临床效果。方法选取2009年6月~2013年12月在我院住院的HFNEF患者90例,随机分为两组,对照组给予利尿剂、ACEI、硝酸酯类等药物常规治疗;治疗组在常规治疗基础上加用Mg-GIK与FDP治疗,10 d为1个疗程。结果治疗组与对照组心功能改善总有效率分别为86.7%、62.2%,两组比较,差异有统计学意义(P〈0.05)。随访3个月,两组再住院率比较差异无统计学意义(P〉0.05)。结论 Mg-GIK与FDP治疗HFNEF能明显改善患者的心功能。 Objective To explore the clinical effect of Mg-GIK combined with FDP treating heart failure with normal ejection fraction(HFNEF). Methods 90 patients with HFNEF hospitalized in our hospital from June 2009 to December2013 were selected.Patients were randomly divided into two groups.Control group was given routine drugs therapy such as diuretic,ACEI and nitrate esters.On the basis of control group,treatment group was given Mg-GIK combined with FDP,and a course of treatment was 10 days. Results The total rate of heart function improvement in treatment group and control group was 86.7% and 62.2% respectively,and the difference was statistical significance(P〈0.05).Patients were followed-up for 3 months,the rehospitalization rate between two groups had no statistical difference(P 〉0.05).Conclusion Mg-GIK combined with FDP treating HFNEF can significantly improve heart function of patients.
出处 《中国当代医药》 2015年第25期45-47,共3页 China Modern Medicine
关键词 葡萄糖-胰岛素-钾盐(极化液) 1 6-二磷酸果糖 射血分数正常心力衰竭 Glucose-insulin-sylvite(polarized solution) FDP Heart failure with normal ejection fraction
  • 相关文献

参考文献17

  • 1Paulus WJ, Tschope C,Sanderson JE,et a/.How to diag-nose diastolic heart failure : a consensus statement on thediagnosis of heart failure with normal left ventricular ejec-tion fraction by the Heart Failure and EchocardiographyAssociations of the European Society of Cardiology [J].EurHeart J,2007,28(20) :2539-2550.
  • 2Hogg K, Swedberg K, Me Murray J. Heart failure with pre-served left ventricular systolic function; epidemiology,clinical characteristics, and prognosis [J].J Am Coll Cardi-ol,2004,43(3) :317-327.
  • 3Owan TE,Hodge DO,Herges RM,ei a/.Trends in preva-lence and outcome of heart failure with preserved ejectionfraction[J].N Engl J Med,2006,355(3) :251-259.
  • 4Kawaguchi M,Hay I,Fetics B^et a/.Combined ventricularsystolic and arterial stiffening in patients with heart failureand preserved ejection fraction : implications for systolicand diastolic reserve limitations [J].Circulation, 2003,107(5):714-720.
  • 5Abozguia K,Clarke K,Lee L,et a/.Modification of myocar-dial substrate use as a therapy for heart failure[J].Nat ClinPract Cardiovasc Med,2006,3(9) :490-498.
  • 6Van Bilsen M,Smeets PJ,Gilde AJ,et a/.Metabolic remod-eling of the failing heart;the cardiac burn-out syndrome.[J].Cardiovasc Res,2004,61 (2): 218-226.
  • 7Azevedo PS,Minicucci MF,Santos PP,et aZ.Energy met-abolism in cardiac remodeling and heart failure[J].CardiolRev,2013,21(3):135-140.
  • 8Fitzgibbons TP,Meyer TE,Aurigemma GP.Mortality in di-astolic heart failure: an update[J].Cardio Rev,2009,17(2):51-55.
  • 9Nassie BM,Carson PE , Mcmurray JJ, et a/.Irbesartan inpatients with heart failure and preserved ejection fraction[J].N Engl J Med, 2008,359 (23) : 2456-2467.
  • 10Hermann F, Ruschitzka FT, Schiffrin EL.Clinical trialsreport.CHARM -Preserved Trial [J].Curr Hypertens Rep,2004,6(1):48-50.

同被引文献7

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部